FDP Medlac 5g Medicine Treatment of myocardial disease due to ischemia (1 bottle + 1 solvent tube)

Dosage form Box
Specifications Acid Fructose-1.6

Ingredient

Composition information	Content
Acid Fructose-1.6	3.75g

Uses

indications

FDP Medlac intravenous powder injected with treatment in the following cases:

Treatment of cardiomyopathy due to ischemia, does not replace the heart therapy.

Used to treat real blood phosphate in acute situations that are using infusion therapy, circulating therapy outside the body, nutrition on the gastrointestinal tract or chronic cases related to the loss of phosphate such as chronic alcohol poisoning, prolonged malnutrition, acute respiratory failure. Learning

fructose-1,6-diiphosphate (FDP Medlac) is an intermediate that has the function of coordinating multiple enzyme reactions in the cell by activating enzymes phosphofructokinase, pyruvate kinase, the concentration of FDP Medlac in cells varies according to each cell line. In red blood cells, the concentration is 6 - 10mg/l.

Biochemical studies on in vito and in vivo show that FDP Medlac will be attached to the cell membrane that facilitates the arrest of potassium, stimulates the accumulation of energy phosphate phosphate and 23-Diphosphoglycerate molecules. Moreover, the FDP Medlac reduces the solving of red blood cells during mechanical injuries and inhibits neutral leukocytes when chemically stimulated, thus limiting the formation of free oxygen roots.

Dynamic pharmacokinetics

Fructose-1,6-diphosphate concentration (FDP Medlac) in plasma 5 minutes after injection at a dose of 250mg/kg in healthy volunteers is 770 mg/ml. 80 minutes after the injection, there is no trace of FDP Medlac.

The half -life is 10-15 minutes. FDP Medlac disappears from plasma due to the permeability of the organization and is hydrolyzed into inorganic and frustose phosphate, which is stimulated by the activity of plasma phosphatase enzymes and red blood cells.

Before taking FDP Medlac 5g Medicine Treatment of myocardial disease due to ischemia (1 bottle + 1 solvent tube)

How to use

The solution must be used up in one injection. If used, they must be left without continued use.

Dosage

depending on the severity of the disease and daily dosage varies from 70 - 160mg of drug powder/kg or in the range of 0.7 - 1.6ml of drug solution after mixing/kg (equivalent to 1-2 vials/day).

In the treatment of sample phosphate, the dose depends on the degree of phosphorus deficiency to avoid excessive increased phosphorus.

In case of high doses, daily dose should be divided.

Dosage for children depends on body weight.

Dosage can be vary depending on age and symptoms.

Preparation of infusion:

Prepare transmission with available transmission tools.

Use the existing fluid set, quickly intravenous infusion of a new drug solution mixed at a speed of about 10ml/min.

Note:

The solution is obtained after a stable phase for at least 24 hours at room temperature (below 25 ° C).

Note: The above dose is for reference only. Specific dosage depends on the condition and level of progression of the disease. For a suitable dose, you need to consult a doctor or medical specialist.What to do when using overdose?

What to do when you forget 1 dose? However, if the time to relax with the next dose is too short, skip the dose and continue the calendar of the drug. Do not use double dose to compensate for missed dose.

Side Effects

When using FDP Medlac drugs often experience unwanted effects (ADR) such as:

Very rarely occur allergic reactions at different levels to anaphylactic shock when transmitting - drugs at speeds of over 10ml/min. Patients may be flushed, brushed their chest drums and the feeling of crawls.

Notify the doctor with unwanted effects when using the drug.

Warnings

Before using the drug you need to read the instructions carefully and refer to the information below.

contraindicated

FDP Medlac intravenous powder in the case:

Hypersensitivity to any ingredients of the drug.

Be cautious when used

Injecting drugs from the vein into the subcutaneous tissue will cause mild pain and local irritation.

The effect of the drug on driving and operating machinery

The drug does not affect the ability to drive and operate machinery.

Use drugs for women during pregnancy and lactation

There is no harmful effect when using FDP Medlac for pregnant women in the last 3 months of pregnancy.

Interactive drug

There is no sign of interaction with other drugs.

Storage

In a dry place, temperatures below 30 ° C, avoid light.

Other drugs

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.